| Effect of rituximab on the progression of rheumatoid arthritis–related interstitial lung disease: 10 years’ experience at a single centre MY Md Yusof, A Kabia, M Darby, G Lettieri, P Beirne, EM Vital, S Dass, ... Rheumatology 56 (8), 1348-1357, 2017 | 206 | 2017 |
| A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features YM El-Sherbiny, A Psarras, MY Md Yusof, EMA Hensor, R Tooze, ... Scientific reports 8 (1), 5793, 2018 | 118 | 2018 |
| Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus MYM Yusof, D Shaw, YM El-Sherbiny, E Dunn, AC Rawstron, P Emery, ... Annals of the rheumatic diseases 76 (11), 1829-1836, 2017 | 113 | 2017 |
| Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases MY Md Yusof, EM Vital, DM McElvenny, EMA Hensor, S Das, S Dass, ... Arthritis & Rheumatology 71 (11), 1812-1823, 2019 | 109 | 2019 |
| Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status MYM Yusof, A Psarras, YM El-Sherbiny, EMA Hensor, K Dutton, ... Annals of the rheumatic diseases 77 (10), 1432-1439, 2018 | 106 | 2018 |
| Brief report: responses to rituximab suggest B cell–independent inflammation in cutaneous systemic lupus erythematosus EM Vital, M Wittmann, S Edward, MY Md Yusof, H MacIver, CT Pease, ... Arthritis & Rheumatology 67 (6), 1586-1591, 2015 | 105 | 2015 |
| Targeting interleukin-6 in rheumatoid arthritis MY Md Yusof, P Emery Drugs 73 (4), 341-356, 2013 | 99 | 2013 |
| Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity A Psarras, A Alase, A Antanaviciute, IM Carr, MY Md Yusof, M Wittmann, ... Nature communications 11 (1), 6149, 2020 | 97 | 2020 |
| The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review AS Zayat, MY Md Yusof, RJ Wakefield, PG Conaghan, P Emery, EM Vital Rheumatology 55 (3), 485-494, 2016 | 84 | 2016 |
| Primary myocardial disease in scleroderma—a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group LA Bissell, MY Md Yusof, MH Buch Rheumatology 56 (6), 882-895, 2017 | 70 | 2017 |
| Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions MYM Yusof, EM Vital, S Das, S Dass, G Arumugakani, S Savic, ... Annals of the rheumatic diseases 74 (9), 1734-1738, 2015 | 50 | 2015 |
| Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus AS Zayat, K Mahmoud, MY Md Yusof, S Mukherjee, MA D’agostino, ... Rheumatology 58 (2), 304-312, 2019 | 40 | 2019 |
| Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a … MYM Yusof, J Arnold, B Saleem, C Vandevelde, S Dass, S Savic, EM Vital, ... The Lancet Rheumatology 5 (2), e88-e98, 2023 | 34 | 2023 |
| Lessons for rituximab therapy in patients with rheumatoid arthritis L Garcia-Montoya, C Villota-Eraso, MYM Yusof, EM Vital, P Emery The Lancet Rheumatology 2 (8), e497-e509, 2020 | 25 | 2020 |
| B cell therapies, approved and emerging: a review of infectious risk and prevention during use MY Md Yusof, EM Vital, MH Buch Current rheumatology reports 17, 1-12, 2015 | 25 | 2015 |
| Certolizumab pegol in rheumatoid arthritis: current update M Fechtenbaum, MY Md Yusof, P Emery Expert opinion on biological therapy 14 (6), 841-850, 2014 | 23 | 2014 |
| B Cell Tetherin: A Flow Cytometric Cell‐Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus YM El‐Sherbiny, MY Md Yusof, A Psarras, EMA Hensor, KZ Kabba, ... Arthritis & Rheumatology 72 (5), 769-779, 2020 | 22 | 2020 |
| Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus K Mahmoud, AS Zayat, Y Yusof, E Hensor, PG Conaghan, P Emery, ... Rheumatology 58 (8), 1353-1360, 2019 | 21 | 2019 |
| Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab J Arnold, S Dass, S Twigg, CH Jones, B Rhodes, P Hewins, ... Rheumatology 61 (12), 4905-4909, 2022 | 20 | 2022 |
| Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis AR Melville, MY Md Yusof, J Fitton, L Garcia-Montoya, L Bailey, S Dass, ... Rheumatology 60 (8), 3679-3688, 2021 | 17 | 2021 |
